I-Mab Biopharma Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From I-Mab Biopharma Co., Ltd
Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.
Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.
Chinese developers forge ahead with research into antibody therapies for COVID-19 as coronavirus variants gain a toe-hold in the country.
Both Nasdaq- and Hong Kong-listed shares in Chinese health-related companies have been free falling with heavy volumes, after foreign investors spooked by China's general crackdown on the tech sector rushed to exit. The two-day sell-off shows high uncertainty and investors' anxiety over the regulatory overreach but underlying fundamentals still seem strong.
- Large Molecule
- Other Names / Subsidiaries
- Tasgen Biotech
- Third Venture Biopharma